Risk factors for lipodystrophy in the CISAI cohort

Paolo Bonfanti, Cecilia Gulisano, Elena Ricci, Lia Timillero, Laura Valsecchi, Silvia Carradori, Luigi Pusterla, Paolo Fortuna, Sebastiano Miccolis, Carlo Magnani, Andrea Gabbuti, Fabio Parazzini, Canio Martinelli, Ivano Faggion, Simona Landonio, Tiziana Quirino, GianMarco Vigevani

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose. - This study set out to describe the frequency of lipodystrophy, and identify its risk factors, in HIV-positive patients treated with HAART containing at least one protease inhibitor (PI). We analyzed the data collected in the CISAI study. Method. - The CISAI is a multicenter cohort study that has enrolled 1480 patients. We assessed whether patients had lipodystrophy at a medical visit, with follow-up visits by the same physician at least every 2 months, and also on the basis of patients' own reports. Results. - The lipodystrophy syndrome was detected in about 25% of the patients. Multivariate analysis showed the risk of lipodystrophy was correlated with female sex (RR 1.5; 95% confidence interval, CI, 1.2-2.1), with older age, with homosexuality (RR 1.5; 95% CI 1.0-2.4), with overt disease (RR 1.4; 95% CI 1.1-1.8) and with the duration of treatment before entering this study. The RR for ritonavir was higher than for the other PI (RR 1.4; 95% CI 0.9-1.9). Among patients receiving concomitant antiretroviral therapy the risk of lipodystrophy was greater with stavudine (RR 1.7; 95% CI 1.3-2.3). Conclusions. - The study confirmed the high frequency of the lipodystrophy syndrome among patients treated with PI.

Original languageEnglish
Pages (from-to)422-427
Number of pages6
JournalBiomedicine and Pharmacotherapy
Volume57
Issue number9
DOIs
Publication statusPublished - Nov 2003

Keywords

  • Adverse reactions
  • Antiretroviral therapy
  • Lipodystrophy
  • Protease inhibitors

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Risk factors for lipodystrophy in the CISAI cohort'. Together they form a unique fingerprint.

Cite this